Your browser doesn't support javascript.
loading
The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Wang, Lexun; Xiang, Lei; Piao, Shenghua; Gong, Xiao; Zhou, Wanxing; Feng, Weixun; Li, Huilin; Li, Leyu; Wei, Aisheng; Zhu, Qing; Rong, Xianglu; Guo, Jiao.
Affiliation
  • Wang L; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou
  • Xiang L; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou
  • Piao S; The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
  • Gong X; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou
  • Zhou W; School of Public Health, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
  • Feng W; Department of Internal Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
  • Li H; Famous Doctor's Studio, Qingyuan Hospital of Traditional Chinese Medicine, Qingyuan, People's Republic of China.
  • Li L; Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
  • Wei A; Department of Endocrinology, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, People's Republic of China.
  • Zhu Q; Department of Endocrinology, Foshan Hospital of Traditional Chinese Medicine, Foshan, People's Republic of China.
  • Rong X; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou
  • Guo J; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou
Diabetes Metab Syndr Obes ; 14: 2651-2659, 2021.
Article in En | MEDLINE | ID: mdl-34163193
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Guideline Language: En Journal: Diabetes Metab Syndr Obes Year: 2021 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Guideline Language: En Journal: Diabetes Metab Syndr Obes Year: 2021 Document type: Article Country of publication: